Paroxetine probably leads to lower participants with at least some Side Effects compared with older ADs (moderate certainty).
Paroxetine showed no clear difference in participants with at least some Side Effects compared with fluvoxamine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with hypericum (moderate certainty).
Paroxetine probably leads to higher failure to remit at endpoint compared with hypericum (moderate certainty).
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with hypericum (moderate certainty).
Paroxetine probably leads to higher participants with at least some Side Effects compared with hypericum (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with milnacipran (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with agomelatine (moderate certainty).
Paroxetine showed no clear difference in failure to remit at endpoint compared with milnacipran (moderate certainty).
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with milnacipran (moderate certainty).
Paroxetine showed no clear difference in participants with at least some Side Effects compared with milnacipran (moderate certainty).
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with mirtazapine (moderate certainty).
Paroxetine probably leads to higher failure to respond at 1‐4 weeks compared with mirtazapine (moderate certainty).
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with mirtazapine (moderate certainty).